Brief: Resverlogix explores potential of Apabetalone in phase 3 Betonmace clinical study
25/05/2016 24:53
May 24 (Reuters) - Resverlogix Corp RVX.TO
* Potential of Apabetalone for treatment of high-risk
diabetes and CKD is being explored in co's phase 3 Betonmace
clinical study
* Says no increase in infections was reported in phase 2
trials
Source text for Eikon: ID:nPreyTYCPa
Further company coverage: RVX.TO
((Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223
8780))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment